Carol Thomas Daily

Amid market dislocation, OIC's oversubscribed fund signals strong investor trust in private credit's role for building America's core infrastructure.

A new report reveals a dangerous paradox: companies are rapidly adopting AI without the security or expertise to manage it, creating a major new threat.

Automotive tech firm Carvix is merging with a SPAC in a billion-dollar deal, aiming to use data and capital to roll up the fragmented auto repair industry.

Publicly traded C1 Fund has acquired a position in Uphold, a move validating the multi-asset platform and highlighting Wall Street's growing crypto appetite.

As The Hanover prepares its Q1 2026 report, investors watch to see if it can sustain momentum amid inflation, high rates, and catastrophe risks.

The direct-to-consumer brand hit a $100M run rate with natural supplements, attracting major investors. But do the scientific claims hold up?

Kenon Holdings announces a $200M dividend fueled by its OPC Energy unit, whose profits soared in 2025, as it completes its strategic exit from shipping.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

Xplor Technologies and Clubessential merge, forming a $900M global leader with a new CEO and a bold eight-figure investment in artificial intelligence.

Australian medtech firm 4DMedical lands CE Mark for its revolutionary CT:VQ lung imaging, fueling a major European expansion with a fresh AU$83M investment.

As Q1 results loom, the gold giant is expected to post strong figures amid high prices. Investors are watching its cash pile, costs, and hybrid AGM.

Karan Dhanelia’s win at Diageo’s World Class signals a major shift, proving elite bartending now thrives far beyond India's traditional metro hubs.

A new training program empowers OBGYNs to offer initial fertility services, promising to shorten patient wait times and reshape the path to starting a family.

As Mochi Health takes the stage at a top women's health summit, a look behind the PR reveals a company battling rapid growth and customer complaints.

Amid a major leadership change, Sonorous Neurovascular pushes its pioneering BosSTENT™ for pulsatile tinnitus sufferers closer to market approval.

EnerSys will unveil its strategic framework and technology roadmap, outlining its plan to navigate the energy transition and capitalize on market growth.

A groundbreaking study of 78,000 people shows most with acne and psoriasis manage their conditions alone, outside the clinic. Here's what it means.

A key recommendation for the drug BIMZELX could soon give Quebec patients a powerful new weapon against the debilitating skin disease hidradenitis suppurativa.

The enclosure manufacturer reversed a 2024 loss, reporting a $282,000 profit for 2025 on a 30.7% revenue surge, signaling a strong market recovery.

As AI reshapes the $10 trillion wellness industry, one franchise doubles down on an old-school approach: human empathy. But can it truly compete?